Published in Cancer Weekly, June 27th, 2006
Study 1: Bone health in prostate cancer patients should be monitored by urologists.
According to a study from Germany, "Many men with prostate cancer are osteoporotic or osteopenic before the initiation of androgen deprivation therapy (ADT). Furthermore, they may develop decreased bone mineral density (BMD) and associated increased risks of skeletal complications during therapy."
"This review provides urologists with information to address bone health issues in men with prostate cancer," explained K. Miller and colleagues,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.